GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00341132 | Liver | Cirrhotic | heterotypic cell-cell adhesion | 25/4634 | 61/18723 | 3.80e-03 | 2.08e-02 | 25 |
GO:0071347 | Liver | Cirrhotic | cellular response to interleukin-1 | 41/4634 | 113/18723 | 4.08e-03 | 2.19e-02 | 41 |
GO:1904035 | Liver | Cirrhotic | regulation of epithelial cell apoptotic process | 35/4634 | 96/18723 | 6.94e-03 | 3.38e-02 | 35 |
GO:00705277 | Liver | Cirrhotic | platelet aggregation | 26/4634 | 67/18723 | 7.53e-03 | 3.57e-02 | 26 |
GO:19030351 | Liver | Cirrhotic | negative regulation of response to wounding | 34/4634 | 94/18723 | 8.84e-03 | 4.08e-02 | 34 |
GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
GO:200123322 | Liver | HCC | regulation of apoptotic signaling pathway | 226/7958 | 356/18723 | 7.26e-16 | 5.68e-14 | 226 |
GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
GO:200123412 | Liver | HCC | negative regulation of apoptotic signaling pathway | 145/7958 | 224/18723 | 1.33e-11 | 5.36e-10 | 145 |
GO:005125822 | Liver | HCC | protein polymerization | 182/7958 | 297/18723 | 4.17e-11 | 1.58e-09 | 182 |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
GO:200123621 | Liver | HCC | regulation of extrinsic apoptotic signaling pathway | 98/7958 | 151/18723 | 2.17e-08 | 5.08e-07 | 98 |
GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
GO:001076922 | Liver | HCC | regulation of cell morphogenesis involved in differentiation | 65/7958 | 96/18723 | 5.17e-07 | 8.37e-06 | 65 |
GO:190002422 | Liver | HCC | regulation of substrate adhesion-dependent cell spreading | 42/7958 | 57/18723 | 1.75e-06 | 2.45e-05 | 42 |
GO:000862511 | Liver | HCC | extrinsic apoptotic signaling pathway via death domain receptors | 55/7958 | 82/18723 | 5.97e-06 | 7.35e-05 | 55 |
GO:00301932 | Liver | HCC | regulation of blood coagulation | 46/7958 | 66/18723 | 7.12e-06 | 8.47e-05 | 46 |
GO:001077022 | Liver | HCC | positive regulation of cell morphogenesis involved in differentiation | 53/7958 | 79/18723 | 8.69e-06 | 1.02e-04 | 53 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGB | SNV | Missense_Mutation | | c.979N>A | p.Asp327Asn | p.D327N | P02675 | protein_coding | deleterious(0) | possibly_damaging(0.753) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
FGB | SNV | Missense_Mutation | | c.1309T>G | p.Cys437Gly | p.C437G | P02675 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AR-A1AW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
FGB | insertion | Nonsense_Mutation | novel | c.59_60insTTATAGTTTGTGAGATTTTCAGATCTTGTCCTCTTAATTGTAATCCTGTATT | p.Leu20PhefsTer5 | p.L20Ffs*5 | P02675 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGB | insertion | Frame_Shift_Ins | novel | c.1365_1366insTGTGTTTGTT | p.Met456CysfsTer11 | p.M456Cfs*11 | P02675 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGB | insertion | Frame_Shift_Ins | novel | c.1366_1367insCTTTATAC | p.Met456ThrfsTer13 | p.M456Tfs*13 | P02675 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGB | insertion | Frame_Shift_Ins | novel | c.790_791insG | p.Lys264ArgfsTer4 | p.K264Rfs*4 | P02675 | protein_coding | | | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
FGB | insertion | Nonsense_Mutation | novel | c.792_793insTTGGTGACTAAATACAAAGTAATTATGTCATAAAC | p.Pro265LeufsTer11 | p.P265Lfs*11 | P02675 | protein_coding | | | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
FGB | SNV | Missense_Mutation | novel | c.1210N>C | p.Phe404Leu | p.F404L | P02675 | protein_coding | tolerated(0.77) | benign(0.018) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | | c.1086N>T | p.Gln362His | p.Q362H | P02675 | protein_coding | tolerated(0.16) | possibly_damaging(0.516) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
FGB | SNV | Missense_Mutation | | c.1330N>A | p.Gly444Ser | p.G444S | P02675 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | RECOMBINANT FACTOR IX FC FUSION PROTEIN | | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | HAEMATOXYLIN | HAEMATOXYLIN | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | eptifibatide | EPTIFIBATIDE | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | ALFIMEPRASE | ALFIMEPRASE | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | abciximab | ABCIXIMAB | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | tirofiban | TIROFIBAN | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | METHYLTHIONINIUM CHLORIDE | METHYLTHIONINIUM CHLORIDE | |